Evaluation of the Efficacy and Treatment-Emergent Adverse Events of Deuruxolitinib for Moderate to Severe Alopecia Areata: A Dose-Ranging Meta-Analysis of 1,372 Randomized Patients

This meta-analysis of 1,372 patients across three randomized controlled trials evaluated the efficacy of deuruxolitinib for moderate to severe alopecia areata (AA). The study found that deuruxolitinib significantly improved hair regrowth, as measured by the SALT score, and increased patient satisfaction, as indicated by the SPRO. Patients showed substantial improvements, with many achieving 75% to 90% improvement from baseline. However, treatment-emergent adverse events (TEAEs) such as elevated creatinine kinase levels, headaches, and acne (notably at the 12 mg dose) were observed but were generally manageable. The study concludes that while deuruxolitinib is promising for AA treatment, further research is needed to ensure long-term safety.